Although participants with baseline CD4 count ≥500 cells/μL were less likely to be receiving concomitant TB treatment and had a lower proportion of males than participants in lower CD4 count strata, these differences are unlikely to have biased outcome measures as neither factor was associated with any of the outcomes in multivariable analyses. Here, CD4 is linked to tuberculosis.